Acute liver failure

The Lancet

Volumn 376, Issue 9736, 2010, Pages 190-201

  Bernal, William ^a   Auzinger, Georg ^a   Dhawan, Anil ^a   Wendon, Julia ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; PARACETAMOL;

AMANITA; BRAIN DISEASE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG INDUCED DISEASE; HEAT SHOCK; HEPATITIS; HEPATITIS A; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS E VIRUS; HUMAN; INCIDENCE; JAUNDICE; LIVER FAILURE; LIVER FUNCTION; LIVER NECROSIS; LIVER TOXICITY; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; VIRUS INFECTION; WATER SUPPLY; WESTERN EUROPE; WILSON DISEASE;

EID: 77955016202     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60274-7     Document Type: Conference Paper

References (154)

1. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734-739
2. Leithead JA, Ferguson JW, Bates CM, et al. The systemic inflammatory response syndrome is predictive of renal dysfunction in patients with non-paracetamol-induced acute liver failure. Gut 2009; 58: 443-449
3. Walsh TS, Wigmore SJ, Hopton P, Richardson R, Lee A. Energy expenditure in acetaminophen-induced fulminant hepatic failure. Crit Care Med 2000; 28: 649-654
4. Clemmesen JO, Kondrup J, Ott P. Splanchnic and leg exchange of amino acids and ammonia in acute liver failure. Gastroenterology 2000; 118: 1131-1139
5. Harry R, Ausinger G, Wendon J. Clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002; 36: 395-402.
6. Molina RA, Katzir L, Rhee C, et al. Early evidence of bone marrow dysfunction in children with indeterminate fulminant hepatic failure who ultimately develop aplastic anemia. Am J Transplant 2004; 4: 1656-1661
7. Antonides C, Berry P, Wendon J, Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol 2008; 49: 845-861
8. Stravitz RT, Larsen F.S. Therapeutic hypothermia for acute liver failure. Crit Care Med 2009; 37 (suppl): S258-64.
9. Parekh NK, Hynan LS, De Lemos J, Lee WM. Elevated troponin I levels in acute liver failure: is myocardial injury an integral part of acute liver failure? Hepatology 2007; 45: 1489-1495
10. Cote GA, Gottstein JH, Daud A, Blei AT. The role of etiology in the hyperamylasemia of acute liver failure. Am J Gastroenterol 2009; 104: 592-597
11. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis 1970; 3: 282-298
12. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993; 342: 273-275 (Pubitemid 23224421)
13. Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl 2008; 14 (suppl 2): S67-79.
14. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986; 6: 97-106.
15. Bhaduri BR, Mieli-Vergani G. Fulminant hepatic failure: pediatric aspects. Semin Liver Dis 1996; 16: 349-355
16. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007; 102: 2459-2463
17. Brandsaeter B, Hockerstedt K, Friman S, et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries. Liver Transpl 2002; 8: 1055-1062
18. Escorsell A, Mas A, de la Mata M, and the Spanish Group for the Study of Acute Liver Failure. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 2007; 13: 1389-1395
19. Wei G, Bergquist A, Broome U, et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med 2007; 262: 393-401.
20. Bernal W, Auzinger G, Wendon J. Prognostic utility of the bilirubin lactate and etiology score. Clin Gastroenterol Hepatol 2009; 7: 249.
21. Hadem J, Stiefel P, Bahr MJ, et al. Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. Clin Gastroenterol Hepatol 2008; 6: 339-345
22. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954
23. Gow PJ, Jones RM, Dobson JL, Angus PW. Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. J Gastroenterol Hepatol 2004; 19: 154-159
24. Sarwar S, Khan AA, Alam A, et al. Predictors of fatal outcome in fulminant hepatic failure. J Coll Physicians Surg Pak 2006; 16: 112-116
25. Khuroo MS, Kamili S. Aetiology and prognostic factors in acute liver failure in India. J Viral Hepat 2003; 10: 224-231
26. Mudawi HMY, Yousif BA. Fulminant hepatic failure in an African setting: etiology, clinical course, and predictors of mortality. Dig Dis Sci 2007; 52: 3266-3269
27. Bhatia V, Singhal A, Panda SK, Acharya S.K. A 20-year single-center experience with acute liver failure during pregnancy: is the prognosis really worse? Hepatology 2008; 48: 1577-1585
28. Acharya SK, Batra Y, Hazari S, Choudhury V, Panda SK, Dattagupta S. Etiopathogenesis of acute hepatic failure: eastern versus western countries. J Gastroenterol Hepatol 2002; 17 (suppl 3): S268-73.
29. Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006; 28: 101-111
30. Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009; 58: 1-27.
31. Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 2004; 22: 4342-4350
32. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294: 202-210
33. Taylor RM, Davern T, Munoz S, et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology 2006; 44: 1589-1597
34. Bianco E, Stroffolini T, Spada E, et al. Case fatality rate of acute viral hepatitis in Italy: 1995-2000: an update. Dig Liver Dis 2003; 35: 404-408
35. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998; 128: 111-114
36. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-290 (Pubitemid 28065254)
37. Sagnelli E, Stroffolini T, Almasio P, et al. Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study. J Viral Hepat 2006; 13: 67-71.
38. Acharya SK, Batra Y, Saraya A, et al. Vaccination for hepatitis A virus is not required for patients with chronic liver disease in India. Natl Med J India 2002; 15: 267-268
39. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008; 8: 698-709.
40. Chadha MS, Walimbe AM, Chobe LP, Arankalle VA. Comparison of etiology of sporadic acute and fulminant viral hepatitis in hospitalized patients in Pune, India during 1978-1981 and 1994-97. Indian J Gastroenterol 2003; 22: 11-15.
41. Dalton HR, Stableforth W, Thurairajah P, et al. Autochthonous hepatitis E in southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol 2008; 20: 784-790
42. Dalton HR, Stableforth W, Hazeldine S, et al. Autochthonous hepatitis E in southwest England: a comparison with hepatitis A. Eur J Clin Microbiol Infect Dis 2008; 27: 579-585
43. Mansuy JM, Abravanel F, Miedouge M, et al. Acute hepatitis E in south-west France over a 5-year period. J Clin Virol 2009; 44: 74-77.
44. Kumar Acharya S, Kumar Sharma P, Singh R, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 2007; 46: 387-394
45. Patra S, Kumar A, Trivedi SS, Puri M, Sarin S.K. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med 2007; 147: 28-33.
46. Bernuau J, Nicand E, Durand F. Hepatitis E-associated acute liver failure in pregnancy: an Indian puzzle. Hepatology 2008; 48: 1380-1382
47. Khuroo MS, Kamili S. Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers. J Viral Hepat 2009; 16: 519-523
48. Kamar N, Selves J, Mansuy J-M, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358: 811-817
49. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273
50. Rantala M, van de Laar MJ.W. Surveillance and epidemiology of hepatitis B and C in Europe-a review. Euro Surveill 2008; 13: 18880.
51. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311 (Pubitemid 38586252)
52. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 1076-1081
53. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15: 89-102.
54. Wai CT, Fontana RJ, Polson J, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 2005; 12: 192-198
55. Umemura T, Tanaka E, Ostapowicz G, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis 2003; 188: 1545-1552
56. Tassopoulos NC, Papatheodoridis GV, Delladetsima I, Hatzakis A. Clinicopathological features and natural history of acute sporadic non-(A-E) hepatitis. J Gastroenterol Hepatol 2008; 23: 1208-1215
57. Fabris P, Biasin MR, Infantolino D, et al. TTV infection in patients with acute hepatitis of defined aetiology and in acute non-A-E hepatitis. J Hepatol 2000; 32: 661-665 (Pubitemid 30180387)
58. Halasz R, Barkholt L, Lara C, et al. Relation between GB virus C/ hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products. Gut 1999; 44: 274-278
59. Gimenez-Barcons M, Forns X, Ampurdanes S, et al. Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. J Hepatol 1999; 30: 1028-1034
60. Bernal W. Changing patterns of causation and the use of transplantation in the United Kingdom. Semin Liver Dis 2003; 23: 227-237
61. Wei G, Kalaitzakis E, Bergquist A, Bjornsson E. Long-term followup of patients with acute liver failure of indeterminate aetiology. Scand J Gastroenterol 2008; 43: 984-991
62. Wigg AJ, Gunson BK, Mutimer DJ. Outcomes following liver transplantation for seronegative acute liver failure: experience during a 12-year period with more than 100 patients. Liver Transpl 2005; 11: 27-34.
63. Tung J, Hadzic N, Layton M, et al. Bone marrow failure in children with acute liver failure. J Pediatr Gastroenterol Nutr 2000; 31: 557-561
64. Gow P, Hathaway M, Gunson B, Heward J, Mutimer D. Association of fulminant non-A non-B hepatitis with homozygosity for HLA A1-B8-DR3. J Gastroenterol Hepatol 2005; 20: 555-561
65. Bernal W, Ma Y, Smith HM, Portmann B, Wendon J, Vergani D. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol 2007; 47: 664-670
66. Bernal W, Cross TJS, Auzinger G, et al. Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol 2009; 50: 306-313
67. Hawton K, Simkin S, Deeks J, et al. UK Legislation on analgesic packs: before and after study of long term effect on poisonings. BMJ 2004; 329: 1076-1081
68. Greene S, Dargan P, Leman P, Jones A. Paracetamol availability and recent changes in paracetamol poisoning: is the 1998 legislation limiting availability of paracetamol being followed? Postgrad Med J 2006; 82: 520-523
69. Gorman DR, Bain M, Inglis JHC, Murphy D, Bateman DN. How has legislation restricting paracetamol pack size affected patterns of deprivation related inequalities in self-harm in Scotland? Public Health 2007; 121: 45-50.
70. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-1372
71. Jalan R, Williams R, Bernuau J. Paracetamol: are therapeutic doses entirely safe? Lancet 2006; 368: 2195-2196
72. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296: 87-93.
73. Temple AR, Lynch JM, Vena J, Auiler JF, Gelotte CK. Aminotransferase activities in healthy subjects receiving three-day dosing of 4, 6, or 8 grams per day of acetaminophen. Clin Toxicol (Phila) 2007; 45: 36-44.
74. Heard K, Green JL, Bailey JE, Bogdan GM, Dart R.C. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007; 26: 283-290
75. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy 2007; 27: 1219-1230
76. Yaghi C, Honein K, Boujaoude J, Slim R, Moucari R, Sayegh R. Influence of acetaminophen at therapeutic doses on surrogate markers of severity of acute viral hepatitis. Gastroenterol Clin Biol 2006; 30: 763-768
77. Rezende G, Roque-Afonso AM, Samuel D, et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 2003; 38: 613-638
78. Davern TJ 2nd, James LP, Hinson JA, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006; 130: 687-694
79. James LP, Alonso EM, Hynan LS, et al. Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics 2006; 118: e676-81.
80. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: 731-739
81. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521
82. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-489
83. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-455
84. Bjornsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006; 38: 33-38.
85. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the united network for organ sharing database. Liver Transpl 2009; 15: 719-729
86. Wai C-T, Tan B-H, Chan C-L, et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007; 27: 465-474
87. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007; 25: 1411-1421
88. Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res 2009; 39: 427-431
89. Huang Y-S, Su W-J, Huang Y-H, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47: 128-134
90. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B.*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genetics 2009; 41: 816-819
91. Lucena MI, Andrade RJ, Martinez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008; 48: 588-596
92. Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132: 272-281
93. Huang Y-S, Chern H-D, Su W-J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889
94. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan M.A. Liver disease in pregnancy. Lancet 2010; 375: 594-605.
95. Ananthakrishnan AN, McGinley EL, Saeian K. Effect of hospital volume and teaching status on outcomes of acute liver failure. Liver Transpl 2008; 14: 1347-1356
96. Bernal W, Auzinger G, Sizer E, Wendon J. Intensive care management of acute liver failure. Semin Liver Dis 2008; 28: 188-200. (Pubitemid 351632958)
97. Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007; 35: 2498-2508
98. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2: 625-631
99. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007; 13: 953-955
100. Ichai P, Duclos-Vallee J-C, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003.
101. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-263
102. Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 2008; 47: 1293-1299
103. Ichai P, Afonso AM, Sebagh M, et al. Herpes simplex virusassociated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl 2005; 11: 1550-1555
104. Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97-101.
105. Prescott L. Paracetamol (acetaminophen): a critical bibliographic review. London: Taylor and Francis, 1996.
106. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324: 1852-1857
107. Wendon JA, Harrison PM, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994; 19: 1407-1413
108. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137: 856-864
109. Bjerring PN, Eefsen M, Hansen BA, Larsen F.S. The brain in acute liver failure. A tortuous path from hyperammonemia to cerebral edema. Metab Brain Dis 2009; 24: 5-14.
110. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 2002; 67: 259-279
111. Vaquero J, Rose C, Butterworth RF. Keeping cool in acute liver failure: rationale for the use of mild hypothermia. J Hepatol 2005; 43: 1067-1077
112. Albrecht J, Norenberg M. Glutamine: a trojan horse in ammonia neurotoxicity. Hepatology 2006; 44: 788-794
113. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999; 29: 648-653
114. Bhatia V, Singh R, Acharya S.K. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 2006; 55: 98-104.
115. Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007; 46: 1844-1852
116. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003; 125: 755-764 (Pubitemid 37070693)
117. Wright G, Shawcross D, Olde Damink SWM, Jalan R. Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis 2007; 22: 375-388
118. Romero-Gomez M, Jover M, Galan JJ, Ruiz A. Gut ammonia production and its modulation. Metab Brain Dis 2009; 24: 147-157
119. Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36: 1163-1171
120. Chatauret N, Desjardins P, Zwingmann C, Rose C, Rao KVR, Butterworth RF. Direct molecular and spectroscopic evidence for increased ammonia removal capacity of skeletal muscle in acute liver failure. J Hepatol 2006; 44: 1083-1088
121. Jiang Q, Jiang X-H, Zheng M-H, Chen Y-P. L-ornithine-L-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2009; 24: 9-14.
122. Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda S.K. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009; 136: 2159-2168
123. Jalan R, Lee WM. Treatment of hyperammonemia in liver failure: a tale of two enzymes. Gastroenterology 2009; 136: 2048-2051
124. Jalan R, Wright G, Davies NA, Hodges SJ. L-ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007; 69: 1064-1069
125. Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology. 2004; 127: 1338-1346
126. Hypothermia to prevent high intracranial pressure in patients with acute liver failure. http://clinicaltrials.gov/ct2/show/ NCT00670124 (accessed April 20, 2010).
127. Murphy N, Auzinger G, Bernal W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004 Feb; 39: 464-470
128. Bhatia V, Batra Y, Acharya S.K. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure-a controlled clinical trial. J Hepatol 2004; 41: 89-96.
129. European liver transplant registry. http://www.ELTR.org. (accessed Sept 23, 2009).
130. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-445 (Pubitemid 19192181)
131. Bernuau J, Goudau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6: 648-651
132. Mochida S, Nakayama N, Matsui A, Nagoshi S, Fujiwara K. Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatology Res 2008; 38: 970-979
133. Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008; 57: 252-257
134. Simpson KJ, Bates CM, Henderson NC, et al. The utilization of liver transplantation in the management of acute liver failure: comparison between acetaminophen and non-acetaminophen etiologies. Liver Transpl 2009; 15: 600-609
135. Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003; 31: 299-305.
136. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005; 41: 26-31.
137. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002; 359: 558-563 (Pubitemid 34178437)
138. Schmidt L, Larsen F. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007; 45: 789-796
139. Katoonizadeh A, Decaestecker J, Wilmer A, et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int 2007; 27: 329-334
140. Burroughs AK, Sabin CA, Rolles K, et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 2006; 367: 225-232
141. van Hoek B, de Boer J, Boudjema K, Williams R, Corsmit O, Terpstra OT; on behalf of the European Auxiliary Liver Transplant Registry Study Group. Auxiliary versus orthotopic liver transplantation for acute liver failure. J Hepatol 1999; 30: 699-705. (Pubitemid 29151913)
142. Quaglia A, Portmann BC, Knisely AS, et al. Auxiliary transplantation for acute liver failure: histopathological study of native liver regeneration. Liver Transpl 2008; 14: 1437-1448
143. Petrowsky H, Busuttil RW. Evolving surgical approaches in liver transplantation. Semin Liver Dis 2009; 29: 121-133
144. Liu CL, Fan ST, Lo CM, et al. Live donor liver transplantation for fulminant hepatic failure in children. Liver Transpl 2003; 9: 1185-1190
145. Campsen J, Blei AT, Emond JC, et al. Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl 2008; 14: 1273-1280
146. Ikegami T, Taketomi A, Soejima Y, et al. Living donor liver transplantation for acute liver failure: a 10-year experience in a single center. J Am Coll Surg 2008; 206: 412-418
147. Surman O. The ethics of partial liver donation. N Engl J Med 2002; 346: 1038.
148. Spital A. More on parental living liver donation for children with fulminant hepatic failure: addressing concerns about competing interests, coercion, consent and balancing acts. Am J Transplant 2005; 5: 2619-2622
149. Hashikura Y, Ichida T, Umeshita K, et al. Donor complications associated with living donor liver transplantation in Japan. Transplantation 2009; 88: 110-114
150. Potts M. Role of living liver donation: surgery violates principles of beneficence and autonomy. BMJ 2003; 327: 1287.
151. Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239: 660-667
152. Liu J, Gluud L, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev 2004; 1: CD003628.
153. Bertani H, Gelmini R, Del Buono MG, et al. Literature overview on artificial liver support in fulminant hepatic failure: a methodological approach. Int J Artif Organs 2002; 25: 903-910
154. Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation 2006; 82: 441-449